Document Detail

Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure.
MedLine Citation:
PMID:  6100609     Owner:  NLM     Status:  MEDLINE    
The mechanism of action of angiotensin converting enzyme (ACE) inhibitors to lower blood pressure remains unclear, but the weight of available data favour peripheral blockade of the formation of angiotensin II (AII). Previous work in rats has shown that the prodrug ACE inhibitor, enalapril (MK-421), lowered blood pressure most effectively when PRA was elevated [sodium deficiency, two-kidney, one figure 8 hypertension, diuretic-treated spontaneously hypertensive rats (SHR)]. In sodium-deficient rats, the enalapril-sensitive component of the blood pressure was greatly reduced after salt loading, and nephrectomy blocked the antihypertensive response to enalapril in SHR. In the present study, further support that the mechanism of action of enalapril involves a reduction in AII has been obtained from rats made hypertensive by continuous intravenous (i.v.) AII infusion for 10 days. Enalapril administered for seven days did not significantly lower blood pressure, suggesting that there were no important non-angiotensin mechanisms (such as bradykinin potentiation) involved in its action. From earlier studies in SHR, the time course for blockade of angiotensin I (AI) pressor responses and the blood pressure reduction did not correspond, suggesting a tissue site of action. In the present studies in adult SHR, a central site of action was ruled out since the parent inhibitor, enalaprilic acid (MK-422), injected into the brain ventricles did not acutely reduce blood pressure. An interaction of enalaprilic acid with the sympathetic nervous system was evaluated in dogs in which adrenergic activity was enhanced as a result of diuretic-induced renin release. Enlaprilic acid did not alter the enhanced hindquarter vasoconstrictor responses to sympathetic nerve stimulation. Enalapril increased renal blood flow, glomerular filtration rate and sodium excretion. The mechanism of the natriuresis in dogs probably involves several mechanisms including a decrease in aldosterone biosynthesis, changes in renal function (glomerular filtration rate and renal blood flow) and possibly blockade of a direct tubular effect of AII on sodium reabsorption. Enalaprlic acid was also studied in a closed chest dog model of acute left ventricular (LV) failure caused by embolization via the left main coronary artery with 50 microns plastic microspheres. Enalaprilic acid at 100 micrograms/kg i.v. reduced preload, afterload and improved LV performance without changing the heart rate. In conclusion, enalapril the prodrug, and enalaprilic acid the active inhibitor, are potentially useful in the treatment of hypertension and LV failure.(ABSTRACT TRUNCATED AT 250 WORDS)
C S Sweet; S L Gaul; P M Reitz; E H Blaine; L T Ribeiro
Related Documents :
3080759 - Central 6-ohda affects both open-field exploratory behaviour and the development of hyp...
12131539 - Brief losartan treatment in young spontaneously hypertensive rats abates long-term bloo...
10826559 - Dietary alpha-lipoic acid supplementation lowers blood pressure in spontaneously hypert...
9730849 - Influences of carvedilol treatment on the effects of acetylcholine on regional haemodyn...
11337009 - Influence of treatment with ca(2+) antagonists on cerebral vasculature of spontaneously...
9667069 - Changes in the gastric vascular network of malignant stroke-prone spontaneously hyperte...
10567189 - Role of renal nerves in the stimulation of the renin system by reduced renal arterial p...
8732989 - Laplace's law and the risks and prevention of bladder rupture after enterocystoplasty a...
25101009 - Time course of corticospinal excitability and autonomic function interplay during and f...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of hypertension. Supplement : official journal of the International Society of Hypertension     Volume:  1     ISSN:  0952-1178     ISO Abbreviation:  J Hypertens Suppl     Publication Date:  1983 Oct 
Date Detail:
Created Date:  1986-02-18     Completed Date:  1986-02-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8501422     Medline TA:  J Hypertens Suppl     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  53-63     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II / pharmacology*
Blood Pressure / drug effects*
Captopril / pharmacology
Enalapril / pharmacology*
Heart Failure / physiopathology*
Heart Ventricles / drug effects,  physiopathology
Hypertension / physiopathology*
Hypertension, Renal / physiopathology
Kidney / physiology
Muscles / blood supply
Rats, Inbred SHR
Renin / blood
Sodium / metabolism
Vasoconstriction / drug effects
Reg. No./Substance:
11128-99-7/Angiotensin II; 62571-86-2/Captopril; 7440-23-5/Sodium; 75847-73-3/Enalapril; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effects of converting enzyme inhibitors on plasma angiotensinogen and plasma aldosterone in sodi...
Next Document:  The clinical pharmacology of enalapril.